Skip to main content

Table 2 Clinical trials of CAR-T therapy on different tumors

From: Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

Tumors

scFv

Single domain

Dose (cells /kg or cells/ m2)

Clinical trials (phage and NCT number) (www.clinicaltrials.gov/)

Number of treated patients

Responses

Persistence

References

ALL

CD19

CD28 + CD3ζ

1.5 × 106 to 3 × 106

Phase I (NCT01044069)

5

5 CR

Uncertaina

[87]

ALL

CD19

CD137+ CD3ζ

1.4 × 106 to 1.2 × 107

Phase I (NCT01626495)

2

2 CR

One persisted 11 months, the other relapsed

[45]

ALL

CD19

41BB + CD3ζ

0.76 × 106 to 20.6 × 106

Phase I/ ΙΙ

(NCT01626495) ( NCT01029366)

30

27 CR

2 to 3 months

[48]

ALL

CD19

CD28 + CD3ζ

3 × 106

Phase I (NCT01044069)

16

14 CR

2 to 3 months

[52]

ALL

CD19

CD28 + CD3ζ

1 × 106 (maximum)

Phase I (NCT01593696)

21

12 CR

Un stated

[13]

CLL

CD19

CD137+ CD3ζ

1.5 × 105

Phase I (NCT01029366)

3

3CR

10 months

[46]

CLL

CD19

CD28 + CD3ζ

0.2–1.1 × 107

Phase I (NCT00466531)

8

1 PR

uncertain

[91]

CLL

CD19

CD28 + CD3ζ

1 × 106, 1.5 × 106, 4 × 106

Phase I (NCT01087294).

10

3 CR

< 1 month

[92]

CLL

CD19

41BB + CD3ζ

0.14 × 108 to 11 × 108

Phase I (NCT01029366)

14

4 CR, 4 PR

14 to 49 months

[49]

CLL

CD19

41BB + CD3ζ

1.6 × 107; 1.0 × 107; 1.46 × 105

Phase I (NCT01029366)

3

2 CR, 1 PR

> 6 months

[93]

CLL/NHL/MM

κ light chain

CD28 + CD3ζ

2 × 107, 1 × 108, 2 × 108

NCT00881920

16 (9 CLL/NHL, 7 MM)

2 CR, 1 PR

6 weeks

[94]

CLL

CD19

CD28 + 41BB+ CD3ζ

2 × 105, 2 × 106, or 2 × 107

unstated

24

4 CR, 10 PR

6 months

[95]

MM

CD19

CD137+ CD3ζ

1 × 107 to 5 × 107

Phase I (NCT02135406)

10

Uncertain

–

[54]

Lymphomas

CD19

41BB+ CD3ζ

3.08 × 106 to 8.87 × 106

NCT02030834

28

16 CR

29.3 months

[47]

NSCLC

EGFR

CD137+ CD3ζ

0.45 to 1.09 × 107

Phase I (NCT01869166)

11

2 PR, 5 SD

2 to 8 months

[20]

CCA

EGFR

CD137+ CD3ζ

2.2/2.1 × 106, 1.22 × 106

Phase I (NCT01869166) (NCT02541370)

1

1 PR

13 months

[63]

CRC

CEA

CD28/CD137+ CD3ζ, CD28+ D137+ CD3ζ

1 × 105 to 1 × 108

Phase I (NCT02349724)

10

7 SD

–

[33]

SVC

MUC1

CD28+  4-1BB+ CD3ζ

5 × 105

Phase I/II (NCT02587689)

1

Tumor necrosis

Unstated

[68]

GBM

GD2

unstated

2 × 107, 5 × 107, 1×  108

Phase I (NCT00085930)

19

3CR

>  6 weeks

[69]

GBM

EGFRvIII

41BB + CD3ζ

1 × 107

Phase I (NCT02209376)

10

1SD

–

[70]

GBM

HER2

CD28+ CD3ζ

1 × 106 to 1 × 108

Phase I (NCT01109095)

17

1 PR,

>  9 months

[71]

7 SD

GBM

IL13Ra2

41BB + CD3ζ

2 × 106, 10 × 106

Phase I (NCT02208362)

1

Tumor necrosis

7.5 months

[72]

Sarcoma

HER2

CD28+ CD3ζ

1 × 104 to 1 × 108

Phase I/II (NCT00902044)

19

4 SD

–

[74]

  1. aFour of these patients were treated with subsequent HSCT